Bank of New York Mellon Corp Decreases Position in Twist Bioscience Co. (NASDAQ:TWST)

Bank of New York Mellon Corp lessened its holdings in Twist Bioscience Co. (NASDAQ:TWST) by 5.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 579,576 shares of the company’s stock after selling 35,373 shares during the period. Bank of New York Mellon Corp owned approximately 0.98% of Twist Bioscience worth $26,933,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Van ECK Associates Corp boosted its position in Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after buying an additional 267 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in shares of Twist Bioscience during the 3rd quarter worth $34,000. Beaird Harris Wealth Management LLC purchased a new stake in shares of Twist Bioscience during the 3rd quarter worth $95,000. KBC Group NV lifted its position in shares of Twist Bioscience by 71.4% during the 4th quarter. KBC Group NV now owns 2,942 shares of the company’s stock worth $137,000 after purchasing an additional 1,226 shares during the last quarter. Finally, Farther Finance Advisors LLC lifted its position in shares of Twist Bioscience by 1,173.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 3,401 shares of the company’s stock worth $154,000 after purchasing an additional 3,134 shares during the last quarter.

Analyst Ratings Changes

TWST has been the subject of several recent analyst reports. JPMorgan Chase & Co. lifted their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research report on Tuesday, February 4th. Wolfe Research initiated coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective for the company. Barclays set a $58.00 price objective on shares of Twist Bioscience and gave the stock an “overweight” rating in a research report on Monday, February 3rd. TD Cowen reaffirmed a “buy” rating and set a $58.00 price objective on shares of Twist Bioscience in a research report on Tuesday, November 26th. Finally, Robert W. Baird lifted their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $54.40.

Insider Transactions at Twist Bioscience

In other news, Director Robert Chess sold 5,000 shares of the business’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $50.00, for a total transaction of $250,000.00. Following the transaction, the director now directly owns 16,641 shares in the company, valued at $832,050. The trade was a 23.10 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Emily M. Leproust sold 1,654 shares of the business’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $44.90, for a total transaction of $74,264.60. Following the transaction, the chief executive officer now owns 673,064 shares in the company, valued at approximately $30,220,573.60. This trade represents a 0.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,007 shares of company stock worth $1,446,933 over the last ninety days. 3.01% of the stock is currently owned by company insiders.

Twist Bioscience Trading Up 0.6 %

NASDAQ TWST opened at $39.43 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. The firm has a market cap of $2.35 billion, a PE ratio of -11.67 and a beta of 2.15. Twist Bioscience Co. has a one year low of $27.41 and a one year high of $60.90. The firm’s fifty day moving average is $46.54 and its two-hundred day moving average is $45.46.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. The company had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. Twist Bioscience’s quarterly revenue was up 24.1% on a year-over-year basis. During the same period in the previous year, the business posted ($0.75) earnings per share. Analysts expect that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.